Comparative Pharmacology
Head-to-head clinical analysis: ACTIFED versus DIMETANE TEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIFED versus DIMETANE TEN.
ACTIFED vs DIMETANE-TEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Dimetane-Ten is a combination of brompheniramine (antihistamine) and phenylephrine (decongestant). Brompheniramine competitively blocks histamine H1 receptors, reducing allergic symptoms; phenylephrine acts as an α1-adrenergic receptor agonist, causing vasoconstriction in nasal mucosa.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
One tablet (chlorpheniramine maleate 4 mg, phenylephrine HCl 10 mg, methscopolamine nitrate 2.5 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (pH-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Terminal elimination half-life: 12-15 hours; clinical context: allows twice-daily dosing; prolonged in renal impairment.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; remainder as minor pathways.
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant/Antihistamine Combination